Equities analysts predict that GW Pharmaceuticals PLC- (NASDAQ:GWPH) will post earnings of ($2.73) per share for the current quarter, according to Zacks. Three analysts have made estimates for GW Pharmaceuticals PLC-‘s earnings. The highest EPS estimate is ($2.39) and the lowest is ($3.00). GW Pharmaceuticals PLC- reported earnings of ($2.43) per share in the same quarter last year, which indicates a negative year over year growth rate of 12.3%. The business is expected to announce its next quarterly earnings report on Monday, February 4th.

On average, analysts expect that GW Pharmaceuticals PLC- will report full year earnings of ($9.24) per share for the current financial year, with EPS estimates ranging from ($11.04) to ($6.24). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.95) per share, with EPS estimates ranging from ($3.48) to $2.28. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, November 27th. The biopharmaceutical company reported ($2.76) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.48) by ($0.28). The firm had revenue of $2.40 million during the quarter, compared to analyst estimates of $2.62 million. GW Pharmaceuticals PLC- had a negative net margin of 1,574.21% and a negative return on equity of 50.93%. GW Pharmaceuticals PLC-‘s quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.14) earnings per share.

Several equities analysts have recently weighed in on the stock. Morgan Stanley set a $227.00 price objective on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research report on Thursday, October 11th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. Stifel Nicolaus started coverage on shares of GW Pharmaceuticals PLC- in a report on Tuesday, August 14th. They set a “buy” rating and a $181.00 price objective on the stock. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a report on Saturday, September 22nd. Finally, Piper Jaffray Companies reiterated an “overweight” rating on shares of GW Pharmaceuticals PLC- in a research report on Monday, November 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $185.38.

Shares of GWPH stock opened at $122.72 on Tuesday. GW Pharmaceuticals PLC- has a 12-month low of $105.12 and a 12-month high of $179.65. The firm has a market cap of $3.83 billion, a PE ratio of -11.62 and a beta of 2.16. The company has a quick ratio of 6.34, a current ratio of 6.66 and a debt-to-equity ratio of 0.01.

Hedge funds have recently bought and sold shares of the business. First Republic Investment Management Inc. lifted its holdings in GW Pharmaceuticals PLC- by 7.4% during the 2nd quarter. First Republic Investment Management Inc. now owns 10,031 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 688 shares during the last quarter. LPL Financial LLC lifted its stake in GW Pharmaceuticals PLC- by 11.4% in the 3rd quarter. LPL Financial LLC now owns 6,799 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 698 shares in the last quarter. Van Hulzen Asset Management LLC lifted its stake in shares of GW Pharmaceuticals PLC- by 29.3% during the 2nd quarter. Van Hulzen Asset Management LLC now owns 3,245 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 735 shares during the period. IFP Advisors Inc lifted its stake in shares of GW Pharmaceuticals PLC- by 103.4% during the 3rd quarter. IFP Advisors Inc now owns 1,448 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 736 shares during the period. Finally, Flagship Harbor Advisors LLC acquired a new stake in shares of GW Pharmaceuticals PLC- during the 2nd quarter worth $109,000. 69.38% of the stock is owned by institutional investors.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Story: Systematic Risk and Investors

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.